Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,600 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 November 2020) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 3MB, 216 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 2635 results:
Author Title [ Type(Asc)] Year
Journal Article
A. Hansell, Hollowell, J., Nichols, T., McNiece, R., and Strachan, D., “Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4)”, Thorax, vol. 54, pp. 413-9, 1999.
S. Rowlands, Devalia, H., and Lawrenson, R., “Use of the combined oral contraceptive pill by under 16s”, J Fam Plann Reprod Health Care, vol. 27, pp. 17-9, 2001.
K. Tascilar, Azoulay, L., Dell'Aniello, S., Bartels, D. B., and Suissa, S., “The Use of Telmisartan and the Incidence of Cancer”, Am J Hypertens, vol. 29, pp. 1358-1365, 2016.
L. Huiart, Dell'Aniello, S., and Suissa, S., “Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer”, Br J Cancer, vol. 104, pp. 1558-63, 2011.
H. J. de Jong, Klungel, O. H., van Dijk, L., Vandebriel, R. J., Leufkens, H. G., van der Laan, J. W., Tervaert, J. W. Cohen, and Van Loveren, H., “Use of statins is associated with an increased risk of rheumatoid arthritis”, Ann Rheum Dis, vol. 71, pp. 648-54, 2012.
C. Becker, Jick, S. S., and Meier, C. R., “Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK”, Drug Saf, vol. 31, pp. 399-407, 2008.
T. P. van Staa, Wegman, S., de Vries, F., Leufkens, B., and Cooper, C., “Use of statins and risk of fractures”, Jama, vol. 285, pp. 1850-5, 2001.
N. C. C. Werkman, Nielen, J. T. H., van den Bergh, J. P. W., Ejskjaer, N., Røikjer, J., Schaper, N. C., Rossi, B., Klungel, O., Vestergaard, P., de Vries, F., and Driessen, J. H. M., “Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation”, Curr Drug Saf, 2020.
A. V. Margulis, Abou-Ali, A., Strazzeri, M. M., Ding, Y., Kuyateh, F., Frimpong, E. Y., Levenson, M. S., and Hammad, T. A., “Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD”, Pharmacoepidemiol Drug Saf, vol. 22, pp. 942-51, 2013.
C. R. Meier, Schlienger, R. G., and Jick, H., “Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction”, Br J Clin Pharmacol, vol. 52, pp. 179-84, 2001.
C. Seliger, Meier, C. R., Becker, C., Jick, S. S., Bogdahn, U., Hau, P., and Leitzmann, M. F., “Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of Glioma”, PLoS One, vol. 11, p. e0149293, 2016.
A. Tran-Duy, Connell, N. J., Vanmolkot, F. H., Souverein, P. C., de Wit, N. J., Stehouwer, C. D. A., Hoes, A. W., de Vries, F., and de Boer, A., “Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study”, J Intern Med, vol. 285, pp. 205-214, 2019.
A. Tran-Duy, Connell, N. J., Vanmolkot, F. H., Souverein, P. C., de Wit, N. J., Stehouwer, C. D. A., Hoes, A. W., de Vries, F., and de Boer, A., “Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study”, J Intern Med, 2018.
R. L. Tannen, Weiner, M. G., and Xie, D., “Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings”, Bmj, vol. 338, p. b81, 2009.
P. Tammes, Sartini, C., Preston, I., Hay, A. D., Lasserson, D., and Morris, R. W., “Use of primary care data to predict those most vulnerable to cold weather: a case-crossover analysis”, Br J Gen Pract, vol. 68, pp. e146-e156, 2018.
L. Azoulay, Yin, H., Filion, K. B., Assayag, J., Majdan, A., Pollak, M. N., and Suissa, S., “The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study”, Bmj, vol. 344, p. e3645, 2012.
A. Keyany, Nielen, J. T. H., Souverein, P. C., de Vries, F., and van den Bemt, B., “Use of parenteral glucocorticoids and the risk of new onset type 2 diabetes mellitus: A case-control study”, Diabetes Res Clin Pract, vol. 139, pp. 100-106, 2018.
P. C. Souverein, Berard, A., van Staa, T. P., Cooper, C., Egberts, A. C., Leufkens, H. G., and Walker, B. R., “Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study”, Heart, vol. 90, pp. 859-65, 2004.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Begaud, B., Zhang, B., and Cooper, C., “Use of oral corticosteroids in the United Kingdom”, Qjm, vol. 93, pp. 105-11, 2000.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Zhang, B., and Cooper, C., “Use of oral corticosteroids and risk of fractures”, J Bone Miner Res, vol. 15, pp. 993-1000, 2000.
J. Gorricho, Garjon, J., Alonso, A., Celaya, M. C., Saiz, L. C., Erviti, J., and Lopez, A., “Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case-control study”, Br J Clin Pharmacol, vol. 83, pp. 2034-2044, 2017.
A. Mitchell, Welsh, T. J., Watson, M. C., Snowball, J., and McGrogan, A., “Use of oral anticoagulants in older people with atrial fibrillation in UK general practice: protocol for a cohort study using the Clinical Practice Research Datalink (CPRD) database”, BMJ Open, vol. 9, p. e032646, 2019.
R. G. Schlienger, Jick, H., and Meier, C. R., “Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction”, Br J Clin Pharmacol, vol. 54, pp. 327-32, 2002.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Use of nonsteroidal anti-inflammatory drugs and risk of fractures”, Bone, vol. 27, pp. 563-8, 2000.
S. J. Roberts and Bateman, D. N., “The use of nitrates, calcium channel blockers and ACE inhibitors in primary care in the Northern Region: a pharmacoepidemiological study”, Br J Clin Pharmacol, vol. 38, pp. 489-97, 1994.
J. Watson, Jones, H. E., Banks, J., Whiting, P., Salisbury, C., and Hamilton, W., “Use of multiple inflammatory marker tests in primary care: using Clinical Practice Research Datalink to evaluate accuracy”, Br J Gen Pract, vol. 69, pp. e462-e469, 2019.
M. Bodmer, Becker, C., Meier, C., Jick, S. S., and Meier, C. R., “Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis”, Cancer Epidemiol Biomarkers Prev, vol. 21, pp. 280-6, 2012.
M. Bodmer, Becker, C., Meier, C., Jick, S. S., and Meier, C. R., “Use of metformin and the risk of ovarian cancer: a case-control analysis”, Gynecol Oncol, vol. 123, pp. 200-4, 2011.
B. B. Smiechowski, Azoulay, L., Yin, H., Pollak, M. N., and Suissa, S., “The use of metformin and the incidence of lung cancer in patients with type 2 diabetes”, Diabetes Care, vol. 36, pp. 124-9, 2013.
B. Smiechowski, Azoulay, L., Yin, H., Pollak, M. N., and Suissa, S., “The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus”, Cancer Epidemiol Biomarkers Prev, vol. 22, pp. 1877-83, 2013.
R. Pradhan, Yin, H., Yu, O. H. Y., and Azoulay, L., “The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study”, Drug Saf, 2019.
T. P. van Staa, Cooper, C., Leufkens, H. G., Lammers, J. W., and Suissa, S., “The use of inhaled corticosteroids in the United Kingdom and the Netherlands”, Respir Med, vol. 97, pp. 578-85, 2003.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Use of inhaled corticosteroids and risk of fractures”, J Bone Miner Res, vol. 16, pp. 581-8, 2001.
L. M. Knapen, van Dalem, J., Keulemans, Y. C., van Erp, N. P., Bazelier, M. T., De Bruin, M. L., Leufkens, H. G., Croes, S., Neef, C., de Vries, F., and Driessen, J. H., “Use of incretin agents and risk of pancreatic cancer: a population-based cohort study”, Diabetes Obes Metab, vol. 18, pp. 258-65, 2016.
L. M. Knapen, de Jong, R. G., Driessen, J. H., Keulemans, Y. C., van Erp, N. P., De Bruin, M. L., Leufkens, H. G., Croes, S., and de Vries, F., “Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study”, Diabetes Obes Metab, vol. 19, pp. 401-411, 2017.
J. Rouette, Yin, H., Pottegard, A., Nirantharakumar, K., and Azoulay, L., “Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer”, Drug Saf, 2020.
Y. Vinogradova, Coupland, C., and Hippisley-Cox, J., “Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases”, Bmj, vol. 364, p. k4810, 2019.
Y. Vinogradova, Coupland, C., and Hippisley-Cox, J., “Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases”, Bmj, vol. 371, p. m3873, 2020.
J. Shawe, Mulnier, H., Nicholls, P., and Lawrenson, R., “Use of hormonal contraceptive methods by women with diabetes”, Prim Care Diabetes, vol. 2, pp. 195-9, 2008.
C. R. Dormuth, Hemmelgarn, B. R., Paterson, J. M., James, M. T., Teare, G. F., Raymond, C. B., Lafrance, J. P., Levy, A., Garg, A. X., and Ernst, P., “Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases”, Bmj, vol. 346, p. f880, 2013.
M. Tuccori, Wu, J. W., Yin, H., Majdan, A., and Azoulay, L., “The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes”, Diabetes Care, vol. 38, pp. 2083-9, 2015.
S. Dial, Delaney, J. A., Barkun, A. N., and Suissa, S., “Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease”, Jama, vol. 294, pp. 2989-95, 2005.
F. Andersohn, Suissa, S., and Garbe, E., “Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction”, Circulation, vol. 113, pp. 1950-7, 2006.
V. Mandilaras, Bouganim, N., Yin, H., Asselah, J., and Azoulay, L., “The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer”, Br J Cancer, vol. 116, pp. 103-108, 2017.
S. Bruderer, Bodmer, M., Jick, S. S., and Meier, C. R., “Use of diuretics and risk of incident gout: a population-based case-control study”, Arthritis Rheumatol, vol. 66, pp. 185-96, 2014.
W. R. der Zanden, de Vries, F., Lalmohamed, A., Driessen, J. H., de Boer, A., Rohde, G., Neef, C., and C. Heijer, den, “Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study”, PLoS One, vol. 10, p. e0139367, 2015.
J. H. Driessen, van Onzenoort, H. A., Henry, R. M., Lalmohamed, A., van den Bergh, J. P., Neef, C., Leufkens, H. G., and de Vries, F., “Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture”, Bone, vol. 68, pp. 124-30, 2014.
A. Douros, Abrahami, D., Yin, H., Yu, O. H. Y., Renoux, C., Hudson, M., and Azoulay, L., “Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes”, Epidemiology, vol. 29, pp. 904-912, 2018.
L. E. Derby, Myers, M. W., and Jick, H., “Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke”, Br J Clin Pharmacol, vol. 47, pp. 565-9, 1999.
L. L. Lanza, McQuay, L. J., Rothman, K. J., Bone, H. G., Kaunitz, A. M., Harel, Z., Ataher, Q., Ross, D., Arena, P. L., and Wolter, K. D., “Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture”, Obstet Gynecol, vol. 121, pp. 593-600, 2013.
[Page last reviewed 6 November 2020]